(19)
(11) EP 1 704 857 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
13.12.2006 Bulletin 2006/50

(43) Date of publication:
27.09.2006 Bulletin 2006/39

(21) Application number: 04808067.5

(22) Date of filing: 22.12.2004
(51) International Patent Classification (IPC): 
A61K 31/05(2006.01)
A61K 31/385(2006.01)
A61P 3/06(2006.01)
A61P 43/00(2006.01)
 A61K 31/122(2006.01)
A61P 3/04(2006.01)
A61P 9/10(2006.01)
(86) International application number:
PCT/JP2004/019717
(87) International publication number:
WO 2005/067904 (28.07.2005 Gazette 2005/30)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

(30) Priority: 15.01.2004 JP 2004007955

(71) Applicant: ASKA Pharmaceutical Co., Ltd.
Minato-ku, Tokyo 108-8532 (JP)

(72) Inventors:
  • YOKOYAMA, Shinji
    Nagoya-shi, Aichi 467-0024 (JP)
  • TSUJITA, Maki
    Nagoya-shi, Aichi 467-0803 (JP)
  • ARAKAWA, Reijiro, c/o Nishitokyo Research Center
    Hamura-shi, Tokyo 205-8501 (JP)
  • AOTSUKA, Tomoji, c/o Nishitokyo Research Center
    Hamura-shi, Tokyo 205-8501 (JP)

(74) Representative: von Kreisler, Alek et al
Patentanwälte von Kreisler-Selting-Werner Postfach 10 22 41
D-50462 Köln
D-50462 Köln (DE)

   


(54) ABCA1 STABILIZER


(57) To provide a pharmaceutically effective prophylactic/preventive agent for low-HDL cholesterolemia, focusing on an HDL-generating mechanism. The ABCA1 stabilizer of the present invention contains a bisphenol-type compound selected form probucol spiroquinone, probucol diphenoquinone, and probucol bisphenol as an effective ingredient. The ABCA1 stabilizer can continuously and stably express ABCA1 by a mechanism quite different from that of conventional processes, and thus is useful as prophylactic/preventive agent for low-HDL cholesterolemia or arteriosclerosis.